Estudo randomizado | Segurança e eficácia da agomelatina em crianças e adolescentes com transtorno depressivo maior que estão recebendo aconselhamento psicológico.

Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries – The Lancet Psychiatry (link para o resumo – $ para o texto completo)

Comentário no Twitter

RCT: 10 to 25 mg/day agomelatine resulted in an improvement versus placebo in CDRS-R raw score of 4·22 (0·63–7·82) at 12 weeks in C&A with MDD, with a similar effect for fluoxetine. The overall effect was confirmed in adolescents, but not in children https://t.co/keecz57fQw

— PfOL (@psychopharmacol) December 23, 2021